About the project


V.A. Cure is a European MSCA-ITN network aiming to uncover core mechanisms of initiation and maintenance of Vascular Anomalies (VAs) and to leverage this information for establishing novel therapeutic strategies. The network consortium consists of 7 academic laboratories and 2 companies from across Europe, and is supported by 8 partner organisations (5 companies, one university, one hospital and a patient organization).

The 14 Early Stage Researchers (ESRs) will be a part of  the unique international PhD program, consisting of an individual research project, the network’s training programme, intersectoral secondments and outreach activities. Project goal is to  ensure a comprehensive perception of the research and drug/technology development in pharma industry/biotech and academia.

The individual research is a part of the V.A. Cure project, which is developed in four stages:

14 Early Stage Researchers to research the causes and mechanisms of aberrant vascular function   A comprehensive training programme provided by experts in vascular biology from across Europe   International cooperation on vascular anomalies research with participating organisations from across the whole chain

Project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 814316